晚期神经内分泌肿瘤患者同期接受177Lu-DOTATATE与卡培他滨治疗:长期结局、毒性、生存与生活质量研究
167例晚期神经内分泌肿瘤患者中,88例接受177Lu-DOTATATE联合口服卡培他滨(1组),79例仅接受177Lu-DOTATATE(2组)。1组部分缓解34%、疾病稳定50.2%、疾病进展6.8%,2组分别为6.3%、60.9%、26.5%;1组中位总生存与无进展生存均未达到,2组均为48个月。联合卡培他滨延长了总生存与无进展生存。
要点
- 1组部分缓解34%、疾病稳定50.2%、疾病进展6.8%,2组分别为6.3%、60.9%、26.5%。
- 1组中位总生存与无进展生存均未达到,2组中位总生存与无进展生存均为48个月。
- Ki-67肿瘤增殖指数与疾病进展风险增加显著相关。
核心结论
- 177Lu-DOTATATE联合卡培他滨治疗延长了总生存与无进展生存。
- 作者认为侵袭性疾病患者可能从这一协同治疗策略中获益。
研究设计与样本
- 1组88例接受每季度177Lu-DOTATATE治疗并联合口服卡培他滨,2组79例仅接受177Lu-DOTATATE治疗。
- 治疗前后按2周、4周和3个月间隔记录血液学、肾功能、肝功能及嗜铬粒蛋白A水平,并分别以嗜铬粒蛋白A趋势和实体瘤疗效评价标准1.1评估生化与形态学疗效。
主要发现
- 177Lu-DOTATATE治疗后血红蛋白水平无显著差异(P=0.4892)。
- 大多数患者血小板水平下降,但所有患者血小板计数均大于100,000/μL,无血小板毒性。
- 未见白细胞相关毒性,2例患者出现肾功能不全,所有患者均未观察到肝毒性。
- 按实体瘤疗效评价标准1.1,1组部分缓解34%、疾病稳定50.2%、疾病进展6.8%,2组部分缓解6.3%、疾病稳定60.9%、疾病进展26.5%。
- 1组中位总生存与无进展生存均未达到,2组中位总生存与无进展生存均为48个月;Ki-67肿瘤增殖指数与疾病进展风险增加显著相关。
关键数值与推荐
- 1组疗效:部分缓解34%、疾病稳定50.2%、疾病进展6.8%。
- 2组疗效:部分缓解6.3%、疾病稳定60.9%、疾病进展26.5%。
- 1组中位总生存与无进展生存均未达到,2组中位总生存与无进展生存均为48个月。
- 177Lu-DOTATATE治疗后血红蛋白水平无显著差异(P=0.4892)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to evaluate the outcome, toxicity, survival, and quality of life in patients with advanced neuroendocrine tumors. METHODS: One hundred sixty-seven patients were enrolled in the study. All patients underwent baseline Ga-DOTANOC PET/CT scans. Lu-DOTATATE therapy was administered quarterly along with oral capecitabine therapy in group 1 patients (n = 88), whereas group 2 patients (n = 79) were treated only with Lu-DOTATATE. Hematologic, kidney function, liver function tests and chromogranin A levels were recorded before and after therapy at 2-week, 4-week, and 3-month intervals. Biochemical and morphological responses were assessed with the trend in chromogranin A levels and Response Evaluation Criteria in Solid Tumors 1.1 criteria, respectively. RESULTS: There was no significant difference in the hemoglobin levels after Lu-DOTATATE therapy (P = 0.4892). In most patients, there was a decrease in the platelet levels; however, all the patients had platelet counts greater than 100,000/μL with no platelet toxicity. There was no toxicity related to leukocytes. Two patients showed renal insufficiencies. No hepatotoxicity was observed in any of the patients. According to Response Evaluation Criteria in Solid Tumors 1.1 criteria, in group 1 patients, the response was partial response in 34% of the patients, stable disease in 50.2%, and progressive disease in 6.8% versus partial response in 6.3%, stable disease in 60.9%, and progressive disease in 26.5% among group 2 patients. The median overall survival (OS) and progression-free survival (PFS) was not reached in group 1 patients. The median OS and PFS in group 2 patients were 48 months. Ki-67 tumor proliferation index was significantly associated with increased risk of disease progression. CONCLUSIONS: Addition of capecitabine therapy with Lu-DOTATATE therapy lengthens the OS and PFS. Patients with aggressive disease may benefit from this synergetic therapeutic approach.
引用
- Ballal S, Yadav MP, Damle NA, et al. Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients With Advanced Neuroendocrine Tumors: A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study. Clin Nucl Med. 2017. PMID: 28872545. doi:10.1097/RLU.0000000000001816
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。